PTC Therapeutics Inc logo

PTCT

PTC Therapeutics Inc

$50.99

Earnings Summary

Revenue
$148.74Mn
Net Profits
$-126.73Mn
Net Profit Margins
-85.2%

Highlights

Revenue:

PTC Therapeutics Inc’s revenue jumped 26.11% since last year same period to $148.74Mn in the Q1 2022. On a quarterly growth basis, PTC Therapeutics Inc has generated -9.98% fall in its revenue since last 3-months.

Net Profits:

PTC Therapeutics Inc’s net profit jumped 1.49% since last year same period to $-126.73Mn in the Q1 2022. On a quarterly growth basis, PTC Therapeutics Inc has generated 11.54% jump in its net profits since last 3-months.

Net Profit Margins:

PTC Therapeutics Inc’s net profit margin jumped 21.88% since last year same period to -85.2% in the Q1 2022. On a quarterly growth basis, PTC Therapeutics Inc has generated 1.74% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the PTC Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.33
EPS Estimate Current Year
-1.33

Highlights

EPS Estimate Current Quarter:

PTC Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.33 - a 11.92% jump from last quarter’s estimates.

EPS Estimate Current Year:

PTC Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.33.

Key Ratios

Key ratios of the PTC Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.78
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-77.4
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

PTC Therapeutics Inc’s earning per share (EPS) jumped 2.73% since last year same period to -1.78 in the Q1 2022. This indicates that the PTC Therapeutics Inc has generated 2.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. PTC Therapeutics Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. PTC Therapeutics Inc’s return on equity (ROE) stands at -77.4.

Dividend Per Share (DPS):

PTC Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-03
-1.51
-1.78
-17.88%

Company Information

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.

Organisation
PTC Therapeutics Inc
Headquarters
South Plainfield, New Jersey, US
Employees
963
Industry
Health Technology
CEO
Stuart Peltz